Journal of Hepatology
Volume 51, Issue 4 , Pages 667-674 , October 2009

Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam

  • Thijs J.W. van de Laar

      Affiliations

    • Cluster of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    • Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5555506; fax: +31 20 5555533.
    • ,
  • Richard Molenkamp

      Affiliations

    • Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Charlotte van den Berg

      Affiliations

    • Cluster of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    • Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Janke Schinkel

      Affiliations

    • Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Marcel G.H.M. Beld

      Affiliations

    • Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Maria Prins

      Affiliations

    • Cluster of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    • Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • Roel A. Coutinho

      Affiliations

    • Cluster of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    • Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands
    • Centre for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    • ,
  • Sylvia M. Bruisten

      Affiliations

    • Cluster of Infectious Diseases, Public Health Service, Nieuwe Achtergracht 100, 1018 WT Amsterdam, The Netherlands
    • Department of Internal Medicine, Centre for Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, The Netherlands

Received 9 September 2008 ,Revised 23 April 2009 ,Accepted 5 May 2009.

References 

  1. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002;129:577–585
  2. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46:1852–1858
  3. Dore GJ, MacDonald M, Law MG, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. Aust Fam Physician. 2003;32:796–798
  4. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46
  5. Jauncey M, Micallef JM, Gilmour S, Amin J, White PA, Rawlinson W, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis. 2004;190:1270–1274
  6. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007;14:413–418
  7. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis. 2004;190:1396–1403
  8. Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis. 2005;192:1701–1709
  9. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001;33:1479–1487
  10. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008;48:1746–1752
  11. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology. 2006;44:1139–1145
  12. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478–1483
  13. Van den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22:183–193
  14. Van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990;162:823–826
  15. Beld M, Penning M, McMorrow M, Gorgels J, van den Hoek A, Goudsmit J. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol. 1998;36:872–877
  16. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990;28:495–503
  17. Beld M, Minnaar R, Weel J, Sol C, Damen M, van der Avoort H, et al. Highly sensitive assay for detection of enterovirus in clinical specimens by reverse transcription-PCR with an armored RNA internal control. J Clin Microbiol. 2004;42:3059–3064
  18. Van de Laar TJ, Langendam MW, Bruisten SM, Welp EA, Verhaest I, Van Ameijden EJ, et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol. 2005;77:509–518
  19. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973
  20. Tamura K, Dudley J, Nei M, Kumar S. Mega4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–1599
  21. Van den Berg CH, Smit C, van Brussel G, Coutinho RA, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454–1462
  22. Aitken CK, McCaw RF, Bowden DS, Tracy SL, Kelsall JG, Higgs PG, et al. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis. 2004;190:1586–1595
  23. Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008;93:148–154
  24. Dore G, Micallef J. Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity. Hepatology. 2007;45:1330
  25. Danta M, Semmo N, Fabris P, Brown D, Pybus O, Sabin C, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008;197:1558–1566
  26. Kamal S. Hepatitis C: a systematic review. Am J Gastroenterol. 2008;103:1283–1297
  27. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat. 2008;15:120–128
  28. Laskus T, Wang LF, Radkowski M, Vargas H, Nowicki M, Wilkinson J, et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol. 2001;75:2059–2066

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00379-1

doi: 10.1016/j.jhep.2009.05.027

Journal of Hepatology
Volume 51, Issue 4 , Pages 667-674 , October 2009

Article Tools

* Image Usage & Resolution